Pharmaceutics Division, College of Pharmacy, University of Texas, Austin, TX 78712, USA.
BMC Cancer. 2011 Mar 28;11:110. doi: 10.1186/1471-2407-11-110.
Double stranded RNA (dsRNA) has multiple anti-tumor mechanisms. Over the past several decades, there have been numerous attempts to utilize synthetic dsRNA to control tumor growth in animal models and clinical trials. Recently, it became clear that intracellular dsRNA is more effective than extracellular dsRNA on promoting apoptosis and orchestrating adaptive immune responses. To overcome the difficulty in delivering a large dose of synthetic dsRNA into tumors, we propose to deliver a RNA replicase-based plasmid DNA, hypothesizing that the dsRNA generated by the replicase-based plasmid in tumor cells will inhibit tumor growth.
The anti-tumor activity of a plasmid (pSIN-β) that encodes the sindbis RNA replicase genes (nsp1-4) was evaluated in mice with model tumors (TC-1 lung cancer cells or B16 melanoma cells) and compared to a traditional pCMV-β plasmid.
In cell culture, transfection of tumor cells with pSIN-β generated dsRNA. In mice with model tumors, pSIN-β more effectively delayed tumor growth than pCMV-β, and in some cases, eradicated the tumors.
RNA replicase-based plasmid may be exploited to generate intracellular dsRNA to control tumor growth.
双链 RNA (dsRNA) 具有多种抗肿瘤机制。在过去的几十年中,人们曾多次尝试利用合成 dsRNA 来控制动物模型和临床试验中的肿瘤生长。最近,人们清楚地认识到,与细胞外 dsRNA 相比,细胞内 dsRNA 在促进细胞凋亡和协调适应性免疫反应方面更为有效。为了克服将大剂量合成 dsRNA 递送到肿瘤中的困难,我们提出了一种基于 RNA 复制酶的质粒 DNA 递送来传递 dsRNA,假设复制酶质粒在肿瘤细胞中产生的 dsRNA 将抑制肿瘤生长。
评估了一种编码辛德毕斯 RNA 复制酶基因 (nsp1-4) 的质粒 (pSIN-β) 在具有模型肿瘤 (TC-1 肺癌细胞或 B16 黑色素瘤细胞) 的小鼠中的抗肿瘤活性,并与传统的 pCMV-β 质粒进行了比较。
在细胞培养中,用 pSIN-β 转染肿瘤细胞可产生 dsRNA。在具有模型肿瘤的小鼠中,pSIN-β 比 pCMV-β 更有效地延迟肿瘤生长,在某些情况下甚至消除了肿瘤。
基于 RNA 复制酶的质粒可能被用来产生细胞内 dsRNA 来控制肿瘤生长。